The results showed that ZOL-FO significantly improved the overall survival (OS) and progression-free survival (PFS) of patients with CLDN18.2-positive, HER2-negative advanced G/GEJ adenocarcinoma compared with placebo plus mFOLFOX6 (PLB-FO), giving new hope for patients with advanced G/GEJ adenocarcinoma. This evidence concerns the gene CLDN18 and gastroesophageal junction adenocarcinoma.